Durvalumab and Tremelimumab with Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma

Trial Identifier: D419CL00025
Sponsor: AstraZeneca
Start Date: July 2025
Primary Completion Date: November 2026
Study Completion Date: March 2028
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN
CN Chengdu, CN
CN Chongqing, CN
CN Guangzhou, CN
CN Hangzhou, CN
CN Hefei, CN
CN Hong Kong, CN
CN Jinan, CN
CN Nanjing, CN
CN Ningbo, CN
CN Shanghai, CN
CN Tianjin, CN
CN Wenzhou, CN
CN Wuhan, CN
CN Xiamen, CN
CN Zhengzhou, CN